[{"address1": "180 North LaSalle Street", "address2": "Suite 1600", "city": "Chicago", "state": "IL", "zip": "60601", "country": "United States", "phone": "844 445 5704", "website": "https://www.xerispharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 377, "companyOfficers": [{"maxAge": 1, "name": "Mr. John P. Shannon", "age": 61, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 918153, "exercisedValue": 0, "unexercisedValue": 148377}, {"maxAge": 1, "name": "Mr. Steven M. Pieper", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 681142, "exercisedValue": 0, "unexercisedValue": 15586}, {"maxAge": 1, "name": "Ms. Beth P. Hecht J.D.", "age": 59, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 695443, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul R. Edick", "age": 67, "title": "Senior Advisor", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1206766, "exercisedValue": 0, "unexercisedValue": 590310}, {"maxAge": 1, "name": "Dr. Kenneth E. Johnson Pharm. D., Pharm.D.", "age": 60, "title": "Senior VP of Global Development & Medical Affairs", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 596967, "exercisedValue": 0, "unexercisedValue": 31173}, {"maxAge": 1, "name": "Ms. Allison  Wey", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  McCulloch", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.32, "open": 2.33, "dayLow": 2.23, "dayHigh": 2.38, "regularMarketPreviousClose": 2.32, "regularMarketOpen": 2.33, "regularMarketDayLow": 2.23, "regularMarketDayHigh": 2.38, "beta": 1.298, "forwardPE": -11.174999, "volume": 940760, "regularMarketVolume": 940760, "averageVolume": 1414156, "averageVolume10days": 1727720, "averageDailyVolume10Day": 1727720, "bid": 2.23, "ask": 2.24, "bidSize": 100, "askSize": 100, "marketCap": 331352160, "fiftyTwoWeekLow": 1.46, "fiftyTwoWeekHigh": 3.26, "priceToSalesTrailing12Months": 1.8265073, "fiftyDayAverage": 2.2984, "twoHundredDayAverage": 2.20745, "currency": "USD", "enterpriseValue": 537913280, "profitMargins": -0.32833, "floatShares": 141888601, "sharesOutstanding": 148256000, "sharesShort": 11410828, "sharesShortPriorMonth": 11087972, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.077, "heldPercentInsiders": 0.0392, "heldPercentInstitutions": 0.42066002, "shortRatio": 9.66, "shortPercentOfFloat": 0.0789, "bookValue": -0.129, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -59564000, "trailingEps": -0.47, "forwardEps": -0.2, "enterpriseToRevenue": 2.965, "enterpriseToEbitda": -21.517, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XERS", "underlyingSymbol": "XERS", "shortName": "Xeris Biopharma Holdings, Inc.", "longName": "Xeris Biopharma Holdings, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8f5f7125-cc84-3c21-a68b-9d3090e24887", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.235, "targetHighPrice": 6.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.58, "targetMedianPrice": 4.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 77568000, "totalCashPerShare": 0.521, "ebitda": -24999000, "totalDebt": 269804000, "quickRatio": 1.59, "currentRatio": 2.257, "totalRevenue": 181412992, "revenuePerShare": 1.284, "returnOnAssets": -0.07037, "freeCashflow": -38892376, "operatingCashflow": -37790000, "revenueGrowth": 0.265, "grossMargins": 0.83721, "ebitdaMargins": -0.1378, "operatingMargins": -0.17033, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-12"}]